Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

By M. Lundblad, Malin Andersson, Christian Winkler, D. Kirik, N. Wierup, M. Cenci. European Journal of Neuroscience, 2002

673 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia (2003, background): “5 mg per kg benserazide, twice daily), which induced a gradual development of abnormal involuntary movements (AIMs”
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. (2007, methodology): “At all tests the AIMs were evaluated according to the rat dyskinesia scale described in detail previously (Lee et al., 2000; Lundblad et al., 2002).”
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease (2011, background): “, 2000) and are reversed by L-DOPA administration (Olsson et al., 1995; Lundblad et al., 2002; Monville et al., 2005; Marin et al., 2007), supporting their use as valid measures of parkinsonian motor features against which to assess the efficacy of new symptomatic drug treatments.”